Phosphate Therapeutics, co-owned and resourced by Shield Therapeutics (Shield), an independent specialty pharmaceutical firm, has selected a global digital clinical research organization (dCRO) Clinipace Worldwide to manage its first major trial in its late stage Nephrology program expected to start in 2014.

Back to News